Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
AstraZeneca
Merck
Medtronic
Harvard Business School

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DOFETILIDE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Dofetilide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00392106 High Intensity Focused Ultrasound (HIFU) Ablation System Study Suspended ProRhythm, Inc. Phase 3 2006-04-01 The purpose of this study is to determine if the HIFU Pulmonary Vein Ablation System is effective in the treatment of paroxysmal Atrial Fibrillation compared to the control of best medical therapy with FDA approved antiarrhythmic drugs.
NCT00657514 Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease Withdrawn Colorado Prevention Center Phase 4 2008-05-01 After 6 weeks of maximal Ranolazine therapy, tissue hemoglobin desaturation kinetics will change compared to placebo in patients with chronic angina and peripheral arterial disease.
NCT01873950 Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects Completed Spaulding Clinical Research LLC Phase 1 2013-05-01 This study seeks to compare 4 known QT prolonging drugs versus placebo to determine their effects on electrophysiological and other clinical parameters. The underlying purpose is to determine if depolarization and repolarization effects caused by drugs with differing ionic channel mechanisms can be distinguished from one another, and to gauge the sensitivity and specificity of novel signal analyses for detection of depolarization and repolarization changes. Secondarily, to evaluate the exposure response relationship and drug induced effects on the heart rate biomarker relationship.
NCT01873950 Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects Completed Food and Drug Administration (FDA) Phase 1 2013-05-01 This study seeks to compare 4 known QT prolonging drugs versus placebo to determine their effects on electrophysiological and other clinical parameters. The underlying purpose is to determine if depolarization and repolarization effects caused by drugs with differing ionic channel mechanisms can be distinguished from one another, and to gauge the sensitivity and specificity of novel signal analyses for detection of depolarization and repolarization changes. Secondarily, to evaluate the exposure response relationship and drug induced effects on the heart rate biomarker relationship.
NCT02308748 Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block Completed Spaulding Clinical Research LLC Phase 1 2014-05-01 The primary objective of this research study is to test the hypothesis that late sodium current blocking drugs (mexiletine or lidocaine) can attenuate the effect of hERG potassium channel blocking drugs (dofetilide) on ventricular repolarization (QTc) by shortening early repolarization (J-Tpeakc). The secondary object is to assess the ability of calcium channel block (diltiazem) to reduce the QTc prolongation associated with hERG block (moxifloxacin).
NCT02308748 Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block Completed Food and Drug Administration (FDA) Phase 1 2014-05-01 The primary objective of this research study is to test the hypothesis that late sodium current blocking drugs (mexiletine or lidocaine) can attenuate the effect of hERG potassium channel blocking drugs (dofetilide) on ventricular repolarization (QTc) by shortening early repolarization (J-Tpeakc). The secondary object is to assess the ability of calcium channel block (diltiazem) to reduce the QTc prolongation associated with hERG block (moxifloxacin).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dofetilide

Condition Name

Condition Name for Dofetilide
Intervention Trials
Long QT Syndrome 2
Drug-induced QT Prolongation 2
Pharmacokinetics 2
Pharmacodynamics 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Dofetilide
Intervention Trials
Long QT Syndrome 4
Peripheral Arterial Disease 1
Angina Pectoris 1
Diabetes Mellitus, Type 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Dofetilide

Trials by Country

Trials by Country for Dofetilide
Location Trials
United States 18
Czech Republic 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Dofetilide
Location Trials
Massachusetts 2
Wisconsin 2
Virginia 1
Texas 1
South Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Dofetilide

Clinical Trial Phase

Clinical Trial Phase for Dofetilide
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Dofetilide
Clinical Trial Phase Trials
Completed 4
Not yet recruiting 1
Recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Dofetilide

Sponsor Name

Sponsor Name for Dofetilide
Sponsor Trials
Spaulding Clinical Research LLC 3
Food and Drug Administration (FDA) 3
Oregon Health and Science University 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Dofetilide
Sponsor Trials
Other 8
U.S. Fed 4
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Medtronic
Express Scripts
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.